Copyright
©The Author(s) 2022.
World J Hepatol. Aug 27, 2022; 14(8): 1608-1620
Published online Aug 27, 2022. doi: 10.4254/wjh.v14.i8.1608
Published online Aug 27, 2022. doi: 10.4254/wjh.v14.i8.1608
CP score | 2 mo | 4 mo |
Worse CP | 9 (36%) | 7 (33.3%) |
Stable CP | 15 (60%) | 12 (57.1%) |
Better CP | 1 (4%) | 2 (9.5%) |
Total | 25 (100%) | 21 (100%) |
Death | 2 | 6 |
Missing | 2 | 2 |
- Citation: De Wilde N, Vonghia L, Francque S, De Somer T, Bagdadi A, Staub E, Lambrechts J, Bucalau AM, Verset G, Van Steenkiste C. Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma. World J Hepatol 2022; 14(8): 1608-1620
- URL: https://www.wjgnet.com/1948-5182/full/v14/i8/1608.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i8.1608